Pretty much a nothing announcement with no indication of potential sales.
After 2 months of not updating shareholders and the market, I would question what is management doing behind the scenes. Now with three executives, our human capital costs will impact our quarterlies so I expected much much more.
However looking at todays high volume and small bots selling maybe there is something other then our cannibas oral trials and this distribution deal.
BDA needs to focus on commercial outcomes leading to uplift in sales or some sort of M&A activity across their sector to spark interest.
BDA Price at posting:
58.0¢ Sentiment: Buy Disclosure: Held
